GLP-1 Resource Center

What is tirzepatide and how is it different from semaglutide?

Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) are both GLP-1 medications but they work differently. Understanding the distinction explains why tirzepatide produces greater average weight loss, and why the nutritional consequences of both are similar despite the mechanistic differences.

Semaglutide: GLP-1 receptor agonist

Semaglutide mimics GLP-1 (glucagon-like peptide-1), a hormone naturally produced in the gut after eating. It activates GLP-1 receptors in the pancreas (stimulating insulin secretion), in the gut (slowing gastric emptying), and in the brain (reducing appetite signals). The STEP 1 trial showed semaglutide at 2.4mg weekly produced average weight loss of 14.9% of body weight over 68 weeks in people without diabetes.

Tirzepatide: dual GIP and GLP-1 receptor agonist

Tirzepatide activates two hormone receptors rather than one. In addition to GLP-1 receptors, it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual activation produces a more pronounced effect on appetite suppression and insulin sensitivity than GLP-1 agonism alone. The SURMOUNT-1 trial showed tirzepatide at 15mg weekly produced average weight loss of 22.5% of body weight, the largest average weight loss ever recorded in a pharmacological trial for obesity at the time of publication.

Side effect profiles

Gastrointestinal side effects, nausea, constipation, vomiting, are common to both medications. In the STEP 1 trial, 44% of semaglutide patients reported nausea. In the SURMOUNT-1 trial, 31% of tirzepatide patients reported nausea at the 15mg dose. Hair loss, sleep disruption, fatigue, and muscle loss are documented with both medications as consequences of rapid caloric restriction rather than direct drug effects.

Why the nutritional consequences are similar

Both medications work primarily by reducing appetite and food intake. Research published in Obesity Reviews in 2026 confirmed that caloric intake drops 16 to 39% across GLP-1 class treatments. The resulting caloric restriction, and the micronutrient, protein, electrolyte, and gut disruption it creates, is consistent across both drug classes.

The TAKE approach

TAKE Essentials are formulated for people on any GLP-1 class medication, semaglutide or tirzepatide, because the nutritional consequences are consistent regardless of which molecule drives the caloric restriction. View The Eight Essentials or start with the GLP-1 Resource Center to identify your most immediate needs.

These statements have not been evaluated by the Food and Drug Administration. TAKE products are not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider about GLP-1 medication options.